Why Gilead Sciences, AbbVie Inc., and Biogen Idec Are Today's 3 Worst Stocks

Eight in 10 sectors and nearly two out of every three stocks finished as winners on Tuesday. Well-versed pessimists know the implications of that: two in 10 sectors were big, fat losers today, and more than one in three stocks ended more loathed than loved. An experienced pessimist might even notice that each of today's hardest-slumping laggards -- Gilead Sciences (NASDAQ: GILD  ) , AbbVie (NYSE: ABBV  ) , and Biogen Idec (NASDAQ: BIIB  ) -- all belong to the health care sector. "Healthcare stocks are going to hell in a handbasket!" they might warn, wishing they had handbasket-makers in their portfolios. Ignoring these imaginary pessimists and their irrational diversification desires, the S&P 500 Index (SNPINDEX: ^GSPC  ) added 6 points, or 0.4%, to end at 1,851.

Gilead Sciences lost 3.1% today, as the chickens finally seem to be coming home to roost. A sharp sell-off in recent weeks among health care and biotech names was originally sparked by Congressional scrutiny upon Gilead itself. Three Democratic congressmen questioned the company's $84,000 annual pricetag for its hepatitis C drug Sovaldi, pointing out that the treatment is of little use to the afflicted if the price point can only be afforded by sultans and kings.

The imaginary pessimist mentioned in the first paragraph may actually be genetically wired to lose money in the stock market, but he or she was right about one thing: health care stocks were a mess on Tuesday. The sector lost 0.7%, the only area of the market to shed more than 0.1% of its value. AbbVie, which makes drugs treating autoimmune diseases, high cholesterol, and Parkinson's disease, among other maladies, tumbled 3% today. Last week AbbVie gave up on a legal dispute against the European Medicines Agency which sought to keep data from its clinical trials private. AbbVie's hasty attempts to keep its data guarded plant nothing but the idea of risk in the mind of investors. And pessimists and investors both despise unnecessary risk. 

Lastly, shares of Biogen Idec shed 2.8% today, as Biogen continued to pay the price for merely being mentioned in the same breath as Gilead. Wall Street has a curious tendency to over-associate one stock with what it believes to be the most direct peers in that industry. The trouble is, sometimes a brief letter from three congressmen to a single company is just as trivial as it sounds; while I don't think Biogen itself is directly threatened by the "scrutiny" on Gilead, Biogen's recent slump shows just how delicately valued the stock was before the pessimists awoke from their slumber.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2907927, ~/Articles/ArticleHandler.aspx, 9/4/2015 10:53:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

John Divine

Fool since 2012, unique fingerprints since birth. Age 7: Put lifetime savings ($18.37!) in the bank, became disillusioned with low interest, and a fascination with the stock market was born.

Today's Market

updated Moments ago Sponsored by:
DOW 16,158.16 -216.60 -1.32%
S&P 500 1,928.58 -22.55 -1.16%
NASD 4,702.65 -30.84 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 10:43 AM
^GSPC $1927.64 Down -23.49 -1.20%
S&P 500 INDEX CAPS Rating: No stars
ABBV $60.16 Down -1.42 -2.31%
AbbVie Inc. CAPS Rating: ****
BIIB $300.87 Down -0.76 -0.25%
Biogen Idec CAPS Rating: ****
GILD $102.72 Up +0.81 +0.79%
Gilead Sciences CAPS Rating: *****